Highland Private Wealth Management Invests $215,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Highland Private Wealth Management acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 364 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Other institutional investors have also recently modified their holdings of the company. Core Alternative Capital grew its holdings in Regeneron Pharmaceuticals by 800.0% during the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 32 shares during the period. ACG Wealth acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $30,000. Delos Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $33,000. Byrne Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $34,000. Finally, Addison Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 220.0% during the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 33 shares during the period. 84.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 10,453 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the transaction, the director now owns 18,408 shares in the company, valued at $11,436,706.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 609 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 9th. The stock was sold at an average price of $741.00, for a total value of $451,269.00. Following the sale, the director now owns 1,082 shares in the company, valued at $801,762. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 10,453 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $621.29, for a total value of $6,494,344.37. Following the completion of the sale, the director now owns 18,408 shares in the company, valued at approximately $11,436,706.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,740 shares of company stock worth $35,478,694. 8.99% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $688.26 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $538.01 and a one year high of $754.67. The company has a market cap of $75.03 billion, a price-to-earnings ratio of 13.74, a PEG ratio of 2.36 and a beta of 0.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12. The business’s 50 day moving average price is $625.11 and its 200 day moving average price is $641.43.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing analysts’ consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The company had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.80 billion. During the same quarter in the previous year, the business posted $27.97 EPS. The business’s quarterly revenue was down 44.4% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.32 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cowen raised their target price on Regeneron Pharmaceuticals from $635.00 to $645.00 in a report on Wednesday, July 20th. Evercore ISI set a $635.00 price objective on Regeneron Pharmaceuticals in a report on Monday, June 20th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $757.00 to $788.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $735.00 to $800.00 and gave the company an “overweight” rating in a report on Monday, September 12th. Finally, Barclays raised their price objective on Regeneron Pharmaceuticals from $735.00 to $815.00 and gave the company an “overweight” rating in a report on Friday, September 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $746.33.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.